BBIO: Strong launches, positive data, and global expansion drive $6–10B sales potential

BridgeBio Pharma, Inc. (BBIO) is currently at $73.26, up $1.80 or 2.52%

• Would be new all-time closing high (Based on available data back to June 27, 2019)
• Would be the first new record closing high since Feb. 8, 2021, when it closed at $72.35
• On pace for largest percent increase since Nov. 24, 2025, when it rose 4.23%
• Snaps a two day losing streak
• Up 166.98% year-to-date; on pace for best year since 2023, when it rose 429.79%
• Up 170.33% from 52 weeks ago (Dec. 4, 2024), when it closed at $27.10
• Would be a new 52-week closing high
• Up 181.99% from its 52-week closing low of $25.98 on Dec. 18, 2024
• Traded as high as $73.45
• Up 2.78% at today's intraday high; largest intraday percent increase since Nov. 24, 2025, when it rose as much as 4.88%

All data as of 11:23:12 AM ET

Source: Dow Jones Market Data, FactSet

Attruby continues to gain first-line market share due to strong clinical data and patient access programs, with further growth expected as diagnosis rates rise and competitors exit. Infigratinib is positioned to disrupt the achondroplasia market as the first oral therapy, while new pipeline assets show robust efficacy and are on track for regulatory filings and launches in 2026-2027.

Based on BridgeBio Pharma, Inc. [BBIO] Piper Sandler 37th Annual Healthcare Conference Audio Transcript — Dec. 2 2025

Attruby continues to gain first-line market share, driven by clinical differentiation and strong patient access programs. Pipeline assets, including infigratinib and Encaleret, show promising data with regulatory filings and launches planned through 2027.

Based on BridgeBio Pharma, Inc. [BBIO] Piper Sandler 37th Annual Healthcare Conference Audio Transcript — Dec. 2 2025

BridgeBio Pharma, Inc. (BBIO) is currently at $73.37, up $1.59 or 2.22%

• Would be new all-time closing high (Based on available data back to June 27, 2019)
• Would be the first new record closing high since Feb. 8, 2021, when it closed at $72.35
• On pace for largest percent increase since Nov. 24, 2025, when it rose 4.23%
• Currently up three of the past four days
• Up 167.38% year-to-date; on pace for best year since 2023, when it rose 429.79%
• Up 176.03% from 52 weeks ago (Dec. 3, 2024), when it closed at $26.58
• Would be a new 52-week closing high
• Up 182.41% from its 52-week closing low of $25.98 on Dec. 18, 2024
• Traded as high as $73.38; highest intraday level since Feb. 9, 2021, when it hit $73.50
• Up 2.23% at today's intraday high

All data as of 11:02:53 AM ET

Source: Dow Jones Market Data, FactSet